NG2/CSPG4's impact on the key hallmarks of GBM and its cell surface expression on both tumor and neovasculature render it an amenable target for immunotherapy using monoclonal antibodies that aid the recognition and destruction of malignant cells via the immune system. Here, CSPG4 is linked to glioblastoma.